Biologic slashes NSAID use in axSpA

Patients with early axial spondyloarthritis who take TNF-alpha inhibitors cut down on their NSAID use, the first “real-life” study confirms.

Nearly 200 patients taking the biologic reduced their mean use of NSAIDs from an ASAS (Assessment of Spondyloarthritis) score of 54.9 at baseline to just 1.9 after two years on the treatment.   

Meanwhile ASAS NSAID scores for 181 matched controls on